THE IMMUNE RESPONSE of immunocompetent mice against syngeneic transplantable tumours is characterized by an early positive phase followed by immunosuppression and progressive tumour growth (Bertschmann et al., 1979; Kuperman et al., 1975) . Lymphocytes capable of lysing tumour targets in vitro can be detected within a week of intradermal injection of tumour cells, but become undetectable after a further 1-2 weeks (Takei et al., 1977 ). An immunogenic tumour growing in its syngeneic host also generates a concomitant anti-tumour immunity, such that the host can specifically suppress the growth of the same tumour implanted at a distant site (Chassoux et al., 1977) . This type of immunity declines as the primary tumour burden increases (Berendt & North, 1980) . The progressive decay of immune effector mechanisms during tumour growth has been ascribed to a number of mechanisms, including inhibition of cell-mediated immunity by serum-blocking factors such as specific antibody (Hellstrom & Hellstrom, 1974) or antigen-antibody complexes (Sjogren et al., 1973) , antigenic modulation of tumour-associated antigens (Aoki & Johnson, 1972) and both specific and nonspecific immunosuppression in the tumour-bearing host due to tumour antigen or tumour products (Gershon et al., 1974; Whitney & Levy, 1975 and against Ly-6.2 which is present on both T and B cells. Lymphocytes were suspended in RPMJ 1640 containing 1% fetal calf serum and 041%0 sodium azide, and aliquots of 106 cells were stained in microtitre plates with saturating levels of directly fluorescein-conjugated monoclonal reagents anti-Thy-I (53-2.1), anti-Lyt-I (53-6.7), anti-Lyt-2 (53-7.3) and anti-ThB (49-h4) (Ledbetter & Herzenberg, 1979 (Oi & Herzenberg, 1979 One week after challenge there were no significant changes in lymphocyte profiles in any of the organs examined. At the end of the second week, however, there was marked regression of the thymus. Vital staining of the residual thymocyte population with acridine orange and ethidium bromide showed many dead cells, and there was a corresponding reduction of viable thymocytes to 1-2%o of normal.
These remaining thymocytes were phenotypically of the mature medullary type (Fig. la, c, e) . Thus, compared to a normal thymocyte population, there was elimination of the very brightly staining Thy-I+ cells (which comprise the majority of normal thymocytes), an increase in the proportion of cells with high Lyt-1 antigenic density (not shown), a reduction in the proportion of Lyt-2+, 3+ cells from -80% in normal mice to 3000 of remaining thymocytes in tumour-bearing mice, and an enrichment in the proportion of Ly-6.2+ cells from -100/ in normal mice up to 70°/ of the remaining thymocytes in tumour-bearing mice. These changes are identical to those obtained 48 h after a single i.p. injection of 125 mg/kg hydrocortisone acetate (Fig. I b, d, f) . note similar changes in the thymus of corticosteroid-treated mice.
The spleens of the tumour-bearing mice were greatly enlarged but contained few The proportion of B cells was also reduced from 55-60% in normal mice to 35-40% in the tumour-bearing mice (Fig.   2c ). Similar population changes were noted in the lymph nodes. T-cell numbers were reduced to 5-10% of normal, most remaining T cells being Lyt-2+.
These observations provide several possible explanations for the immunosuppression which is known to develop during tumour progression. Previous workers have demonstrated an initial positive immune response to EL-4 by C57BL/6 mice 1 week after tumour challenge (Apffel et al., 1966; Kemp et al., 1973) . At this time we were unable to detect any changes in the overall lymphocyte populations in the spleen, lymph nodes and thymus, which is consistent with an uncompromised immune response. Later, when the immune response is known to be diminished, we detected characteristic selective lymphocytolysis. This, of itself, would be expected to diminish the potential immune rsponse and, since at this time of tumour growth almost all lymphocytes are of the Lyt-2+ subclass, these could be immuno-incompetent due to lack of Lyt-l+, 2-helper cells. Recently, the nonreactivity of cortical Lyt-2+ thymocytes in developing into cytotoxic T cells was shown to be due to lack of Lyt-l+, 2-helper cells rather than inherent immuno-incompetence (Wagner et al., 1980) . Our data are also consistent with the considerable volume of evidence that immunogenic tumours induce the generation of suppressor cells in functionally dominant numbers (Perry et al,. 1978; Kuperman et al., 1975) though as yet we have not characterized the Lyt-2+ population found in our experiments as suppressive. However, perhaps the most interesting observation derived from this work is the similarity between the effects of tumour growth and the administration of a pharmacological dose of corticosteroid on both the thymus (Fig. 1) and peripheral lymphoid organs. Corticosteroid is used as a nonspecific immunosuppressant, though the mechanism of its action is unclear. We have recently shown that Lyt-2+ cells are selectively resistant to corticosteroid, both in peripheral lymphoid organs (Rogers & Matossian-Rogers, 1982) and also within the putative mature thymocyte population (Rogers & Matossian-Rogers, 1981) . There was a dose-related increase of the Lyt-2+ splenic population from 30% up to 60% of total remaining T lymphocytes 48 h after a single injection of hydrocortisone acetate in doses ranging from 62-5 to 500 mg/kg. In the thymus, the lowest dose of steroid caused a reduction of the Lyt-2+ population from 80 to 30%; thereafter, there was a dose-related increase of Lyt-2+ cells. Thus not only are the thymocyte profiles of tumour-bearing mice similar to steroid-treated animals ( Fig. 1) but the reduction in lymphocyte numbers and relative increase in Lyt-2+ cells in peripheral lymphoid organs of tumour-bearing mice (Fig. 2a, b) are also characteristic of steroid treatment. This suggests that the mechanism of action in both cases may be similar, and that tumours may thereby have a marked nonspecific immunosuppressant role.
One further interesting feature from this work was the high percentage of null cells that we found in the spleen and lymph node. The spleens of the tumour-bearing mice were enlarged 2 weeks after tumour injection; most of the splenocytes were large null cells outside the size range of lymphocytes. Furthermore, of those cells within lymphocyte size range, 45% were null-staining cells. We do not know the origin or function of these cells but in view of their prevalence we are currently trying to determine their significance.
Although this work was performed using the C57BL/6, EL-4 model, we have noted similar thymic regression in many other host-tumour combinations and have confirmed the selection of mature thymocytes by FACS analysis in DBA/2 mice given the L5178Y tumour.
